inclusion criteria: 1. subjects must have a positive test for sars-cov-2. 2. covid-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to screening 3. subjects should be ordinal scale for clinical improvement score of 4 or less. 4. subjects receiving oxygen should have pulse oximetry ≥ 93% on 3 liters per minute of oxygen or less delivered by nasal prongs. 5. subjects can be receiving standard of care (soc) for covid-19, this includes marketed therapies or therapies with emergency use authorization (eua) for covid-19 treatment. 6. subject's spirometry (fev1 and forced vital capacity \[fvc\]) must be ≥70% of predicted value. 7. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being \< 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. 8. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. 9. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. 10. must have the ability to understand and give informed consent.

inclusion criteria: 1. subjects must have a positive test for sars-cov-2. 2. covid-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to screening 3. subjects should be ordinal scale for clinical improvement score of 4 or less. 4. subjects receiving oxygen should have pulse oximetry ≥ 93% on 3 liters per minute of oxygen or less delivered by nasal prongs. 5. subjects can be receiving standard of care (soc) for covid-19, this includes marketed therapies or therapies with emergency use authorization (eua) for covid-19 treatment. 6. subject's spirometry (fev1 and forced vital capacity \[fvc\]) must be ≥70% of predicted value. 7. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being \< 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. 8. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. 9. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. 10. must have the ability to understand and give informed consent.

inclusion criteria: subjects must have a positive test for sars-cov-2. covid-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to screening subjects should be ordinal scale for clinical improvement score of 4 or less. subjects receiving oxygen should have pulse oximetry ≥ 93% on 3 liters per minute of oxygen or less delivered by nasal prongs. subjects can be receiving standard of care (soc) for covid-19, this includes marketed therapies or therapies with emergency use authorization (eua) for covid-19 treatment. subject's spirometry (fev1 and forced vital capacity [fvc]) must be ≥70% of predicted value. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being < 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. must have the ability to understand and give informed consent.

inclusion criteria: subjects must have a positive test for sars-cov-2. covid-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to screening subjects should be ordinal scale for clinical improvement score of 4 or less. subjects receiving oxygen should have pulse oximetry ≥ 93% on 3 liters per minute of oxygen or less delivered by nasal prongs. subjects can be receiving standard of care (soc) for covid-19, this includes marketed therapies or therapies with emergency use authorization (eua) for covid-19 treatment. subject's spirometry (fev1 and forced vital capacity [fvc]) must be ≥70% of predicted value. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being < 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. must have the ability to understand and give informed consent.

inclusion criteria: 1. subjects must have a positive test for sars-cov-2. 2. covid-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to screening 3. subjects should be ordinal scale for clinical improvement score of 4 or less. 4. subjects receiving oxygen should have pulse oximetry ≥ 93% on 3 liters per minute of oxygen or less delivered by nasal prongs. 5. subjects can be receiving standard of care (soc) for covid-19, this includes marketed therapies or therapies with emergency use authorization (eua) for covid-19 treatment. 6. subject's spirometry (fev1 and forced vital capacity [fvc]) must be ≥70% of predicted value. 7. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being < 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. 8. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. 9. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. 10. must have the ability to understand and give informed consent.

inclusion criteria: 1. subjects must have a positive test for sars-cov-2. 2. covid-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to screening 3. subjects should be ordinal scale for clinical improvement score of 4 or less. 4. subjects receiving oxygen should have pulse oximetry ≥ 93% on 3 liters per minute of oxygen or less delivered by nasal prongs. 5. subjects can be receiving standard of care (soc) for covid-19, this includes marketed therapies or therapies with emergency use authorization (eua) for covid-19 treatment. 6. subject's spirometry (fev1 and forced vital capacity [fvc]) must be ≥70% of predicted value. 7. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being < 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. 8. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. 9. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. 10. must have the ability to understand and give informed consent.

inclusion criteria: 1. subjects must have a positive test for sars-cov-2. 2. covid-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to screening 3. subjects should be ordinal scale for clinical improvement score of 3 or less 4. pulse oximetry ≥ 93% on room air 5. subjects must be receiving standard of care (soc) for covid-19, this includes marketed therapies used for covid-19 treatment. 6. subject's spirometry (fev1 and forced vital capacity [fvc]) must be ≥70% of predicted value. 7. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being < 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. 8. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. 9. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. 10. must have the ability to understand and give informed consent.

inclusion criteria: 1. subjects must have a positive test for sars-cov-2. 2. covid-19 signs and symptoms such as (fever, cough, shortness of breath or fatigue) with onset within the 7 days prior to screening 3. subjects should be ordinal scale for clinical improvement score of 3 or less 4. pulse oximetry ≥ 93% on room air 5. subjects must be receiving standard of care (soc) for covid-19, this includes marketed therapies used for covid-19 treatment. 6. subject's spirometry (fev1 and forced vital capacity [fvc]) must be ≥70% of predicted value. 7. if female, the subject must be surgically sterile or ≥ 1 year postmenopausal. if of child-bearing potential (including being < 1years postmenopausal) and, if participating in sexual activity that may lead to pregnancy, the subject agrees to use an effective dual method of birth control (acceptable methods include intrauterine device, spermicide, barrier, male partner surgical sterilization, and hormonal contraception) during the study and through 30 days after completion of the study. 8. if female, must not be pregnant, plan to become pregnant, or nurse a child during the study and through 30 days after completion of the study. a pregnancy test must be negative at the screening visit, prior to dosing on day 1. 9. if male, must be surgically sterile or, if not surgically sterile and if participating in sexual activities that may lead to pregnancy, be willing to practice two effective methods of birth control (acceptable methods include barrier, spermicide, or female partner surgical sterilization) during the study and through 30 days after completion of the study. 10. must have the ability to understand and give informed consent.